ArticleBMC geriatrics2025
Impact of SARS-CoV-2 subvariants on postoperative outcomes in geriatric hip fracture patients - a multinational multicentre study.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHip fractures (HF) are among the most prevalent diagnoses in geriatric traumatology, with persistently high incidence even during the COVID-19 pandemic. Concomitant SARS-CoV-2 infection adds clinical complexity and has been associated with increased mortality and prolonged hospitalisation. This study aimed to assess the impact of SARS-CoV-2 subvariants B.1.1.7 (Alpha), B.1.617.2 (Delta), and B.1.1.529 (Omicron) on postoperative outcomes in patients undergoing surgical treatment for HF.
methodsA retrospective multicentre study was conducted using data from the German Registry for Geriatric Trauma (ATR-DGU
resultsDuring the Alpha period, in-hospital mortality and length of stay were similar between COVID-19-comorbid (8.3%, 13 days) and SARS-CoV-2-negative patients (5.4%, 15 days). In the Delta and Omicron periods, mortality was significantly higher among COVID-19-comorbid patients (14.3% and 13.9%) compared to SARS-CoV-2-negative patients (5.8%, p = 0.017; 5.7%, p < 0.001), with longer hospitalisations (17 vs. 15 days, p < 0.05). COVID-19-comorbid patients were more frequently institutionalised and exhibited lower levels of pre-fracture mobility compared to SARS-CoV-2-negative patients.
conclusionCOVID-19-positive patients showed lower mortality during the Alpha period and higher mortality during the Delta and Omicron periods. Overall, COVID-19 comorbidity was associated with increased in-hospital mortality and longer hospitalisation. These observations may be influenced by unmeasured confounding.
trial registrationNot applicable. This retrospective study used anonymized data from the German Registry for Geriatric Trauma (ATR-DGU
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.